Thermo Fisher Scientific Inc. $TMO Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 526,587 shares of the medical research company’s stock after selling 246,822 shares during the period. Ensign Peak Advisors Inc owned 0.14% of Thermo Fisher Scientific worth $213,510,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TMO. Quilter Plc boosted its holdings in shares of Thermo Fisher Scientific by 15.0% in the second quarter. Quilter Plc now owns 276,111 shares of the medical research company’s stock valued at $111,952,000 after acquiring an additional 35,983 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $114,706,000. Empirical Finance LLC raised its stake in shares of Thermo Fisher Scientific by 3.6% during the 2nd quarter. Empirical Finance LLC now owns 13,915 shares of the medical research company’s stock worth $5,642,000 after buying an additional 489 shares in the last quarter. Sierra Legacy Group lifted its holdings in shares of Thermo Fisher Scientific by 209.3% in the 2nd quarter. Sierra Legacy Group now owns 1,970 shares of the medical research company’s stock valued at $799,000 after buying an additional 1,333 shares during the period. Finally, Investidor Profissional Gestao de Recursos Ltda. grew its holdings in Thermo Fisher Scientific by 75.8% during the second quarter. Investidor Profissional Gestao de Recursos Ltda. now owns 25,749 shares of the medical research company’s stock worth $10,440,000 after acquiring an additional 11,101 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $573.39 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market cap of $215.43 billion, a PE ratio of 33.12, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a 50-day simple moving average of $533.28 and a 200-day simple moving average of $471.15. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the business earned $5.28 earnings per share. Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share repurchase plan on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total value of $5,844,814.50. Following the transaction, the vice president owned 14,145 shares in the company, valued at $8,085,564.90. This trade represents a 41.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 51,845 shares of company stock valued at $28,956,952 over the last 90 days. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on TMO shares. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. TD Cowen boosted their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $601.65.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.